How to Help Your Patients Save Money on Myrbetriq: A Provider's Guide to Savings Programs

The cost of Myrbetriq (mirabegron) is one of the most common barriers your patients will raise at follow-up. Brand-name Myrbetriq lists at $457+ per 30-tablet supply, and while generic mirabegron is now available, patent litigation has kept the generic market inconsistent. This guide equips prescribers, nurses, and office staff with a clear, current map of every meaningful savings pathway available in 2026.

Understanding the Myrbetriq Cost Landscape in 2026

Before directing a patient to a savings program, it helps to understand where the cost problem originates:

• Brand-name Myrbetriq: Retail ~$457-$625 for 30 tablets. Insurance typically classifies it as Tier 3-4 with a higher copay or requires step therapy/prior auth.
• Generic mirabegron ER: Available from some manufacturers (e.g., Alkem) but not all (Lupin and Zydus blocked by court order as of April 2025). GoodRx pricing as low as $117/month at some pharmacies. Inconsistent stock means patients may still struggle to fill it.
• Insurance step therapy: UnitedHealthcare (effective 11/16/2025) requires documented failure of two OAB alternatives before covering generic mirabegron. Other plans have similar requirements.

Savings Program 1: Astellas Momentum Savings Card

The Momentum Savings Card is the manufacturer's copay assistance program for brand Myrbetriq. Here's what your office needs to know:

• Who qualifies: Commercially insured patients (not Medicare, Medicaid, or any government-sponsored program)
• Benefit: Covers up to $70/month on Myrbetriq copay; maximum $840/year (12 fills). Patient is responsible for first $20 plus any amount over $90 per fill.
• Enrollment: Patient can enroll at AstellasPharmaSupportSolutions.com or by calling 1-866-666-8244 (Monday-Friday, 8 a.m.-8 p.m. ET). The card can be printed immediately for retail pharmacy use.
• Mail-order caveat: Not all mail-order pharmacies accept the card. If the patient uses mail-order, they should verify with their pharmacy. For non-accepting mail-order pharmacies, a Direct Member Reimbursement (DMR) form is available.
• Office role: No office paperwork required. Simply inform patients about the card and direct them to enroll independently. Consider printing enrollment info for your patient handout materials.

Savings Program 2: Astellas Patient Assistance Program (PAP)

For patients who are uninsured, underinsured, or whose insurance excludes Myrbetriq coverage, the Astellas Patient Assistance Program provides brand Myrbetriq at no cost to eligible patients. This program requires more office coordination than the savings card:

• Eligibility criteria: Patient must be 18+, have a valid Myrbetriq prescription for an FDA-approved indication, meet income eligibility requirements, and have a valid U.S. address
• Prescriber's role: The application requires prescriber signature and information. Your office staff can help initiate and complete the paperwork.
• Contact: Call 1-800-477-6472 (Monday-Friday, 9 a.m.-8 p.m. ET) or visit AstellasPharmaSupportSolutions.com. Astellas Pharma Support Solutions staff can determine eligibility and guide enrollment.

Savings Program 3: Generic Mirabegron + Discount Cards

For patients who can tolerate a switch to generic mirabegron ER, third-party discount programs offer substantial savings without any enrollment or paperwork:

• GoodRx: Generic mirabegron ER as low as $117.62 for 30 tablets (73% off average retail of ~$441) at participating pharmacies. Available at GoodRx.com or the GoodRx app — no enrollment needed.
• SingleCare: Generic mirabegron ~$189 at participating pharmacies. Compare pharmacy prices by zip code at SingleCare.com.

Important clinical note for patients switching to generic: FDA-approved generic mirabegron ER is bioequivalent to brand Myrbetriq — same active ingredient, same therapeutic effect. Most patients switch seamlessly. A small number may notice differences due to inactive ingredient variations. Counsel patients that any concerning changes in response or new side effects after switching should be reported.

Handling Step Therapy and Prior Authorization

When insurance requires step therapy before covering Myrbetriq, your documentation is the key to a swift PA approval or exception:

1. Document prior OAB treatment history. Record any previously tried anticholinergic OAB drugs, doses used, duration, and reasons for discontinuation (side effects, inadequate response, etc.).
2. Document clinical contraindications. For patients where antimuscarinics are medically inappropriate (narrow-angle glaucoma, cognitive impairment, urinary retention risk), document this clearly in the chart to support an exception to step therapy requirements.
3. Use Astellas Pharma Support Solutions. APSS staff assist with benefit verification and the prior authorization process. Call 1-800-477-6472 or 1-866-666-8244 for support.

Recommended Provider Workflow for Myrbetriq Cost Issues

1. Check patient's insurance formulary for Myrbetriq/mirabegron tier and PA requirements before prescribing
2. If commercially insured: inform patient about Momentum Savings Card
3. If uninsured/underinsured: initiate PAP application with staff assistance
4. For cash-pay patients: direct to GoodRx for generic mirabegron (~$117 minimum)
5. If step therapy is required: submit PA with documented prior treatment history and any contraindications
6. If pharmacy stock is the issue (not cost): refer patients to medfinder.com to locate pharmacies with Myrbetriq in stock

For more provider resources, visit medfinder for providers and see How to Help Your Patients Find Myrbetriq in Stock.